JAC Advance Access originally published online on June 10, 2005
Journal of Antimicrobial Chemotherapy 2005 56(2):265-269; doi:10.1093/jac/dki194
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2005
Leading article |
Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons
Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS G-19, Atlanta, GA 30333, USA
* Tel: +1-404-639-4987; Fax: +1-404-639-1174; E-mail: GGarcia-lerma{at}cdc.gov
The introduction of highly active antiretroviral therapy (HAART) has resulted in a significant decrease in HIV and AIDS-related mortality and morbidity. However, these treatments can select for drug-resistant viruses which are associated with poor virological responses to the antiretroviral therapy and possible loss of clinical benefit. Drug-resistant viruses can also be transmitted between individuals. In the absence of drug pressure, transmitted drug-resistant viruses gradually lose resistance mutations that confer a selective disadvantage as they evolve to more fit viruses. As a result, unusual resistance-related genotypes not commonly seen in treated patients may arise in the population. Viruses with unique patterns of thymidine analogue-associated mutations (TAMs) have now been identified in a substantial proportion of treatment-naive recently diagnosed persons. In this leading article, I discuss these findings and the potential impact of these unique reverse transcriptase (RT) genotypes on evolution of resistance and treatment responses.
Keywords: revertant viruses , fitness , virus evolution
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. L. Booth and A. M. Geretti Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection J. Antimicrob. Chemother., June 1, 2007; 59(6): 1047 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-e. Cong, W. Heneine, and J. G. Garcia-Lerma The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions J. Virol., March 15, 2007; 81(6): 3037 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Booth, A. M. Garcia-Diaz, M. S. Youle, M. A. Johnson, A. Phillips, and A. M. Geretti Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection J. Antimicrob. Chemother., March 1, 2007; 59(3): 517 - 524. [Abstract] [Full Text] [PDF]
|
|